NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Claris Bio

Claris Bio

Private
Jersey City, New JerseyHealthcare & Life Scienceshttps://clarisbio.com/

Last Round

Series B

Jul 28, 2026

Total Funding Raised

$175M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Claris Bio is a biotechnology company that specializes in the development of topical formulation technology for the treatment of orphan ophthalmic disorders and corneal diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyophthalmic therapeuticsdrug developmentocular surface diseasebiopharmarecombinant biologicsclinical stage biotechophthalmologytherapeutic pipelineintellectual propertydrug discoverybiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Claris Bio Comparables

Compare Claris Bio with similar companies based on industry and business-model similarity.

Claris Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Selagine, Inc.
86%
TearSolutions
86%
iView Therapeutics
85%

Claris Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 28, 2026
Series AJan 4, 2024

Claris Bio Investors

Notable investors and investment history

Claris Bio investors
InvestorRounds
Janus Henderson GroupSeries B, Series A
RA Capital ManagementSeries A
Mass General Brigham InnovationSeries B, Series A
Catalio Capital ManagementSeries B
Novo HoldingsSeries B, Series A
Aisling CapitalSeries B
Adage Capital ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 20, 2026

    Grew 233% QoQ, from 3 to 10 employees.

  • Apr 22, 2026

    Grew 600% QoQ from 1 to 7 employees.

Claris Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Claris Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Claris Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersJersey City, New Jersey
Employee Range14
Year Founded2020
Last FundingJul 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.